Xultophy: combination therapy for the treatment of type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1931-2253|26|17|32-34

ISSN： 0959-6682

Source： PRESCRIBER, Vol.26, Iss.17, 2015-09, pp. : 32-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

By Schwartz Stanley  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3009-3022

Informa Healthcare

Access to resources Recommend Favorite

Lipid management in Type 2 diabetes: the case for combination therapy?

By Saely Christoph H   Drexel Veronika   Vonbank Alexander   Drexel Heinz  

Therapy, Vol. 8, Iss. 2, 2011-03 ,pp. : 129-141

Future Medicine

Access to resources Recommend Favorite

Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

By Derosa Giuseppe   Salvadeo Sibilla AT   Cicero Arrigo FG  

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 559-569

Future Medicine

Access to resources Recommend Favorite

Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 497-507

John Wiley & Sons Inc

Access to resources Recommend Favorite

Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite